John W. Hubbard

Biography

Dr. John W. Hubbard, Ph.D., FCP, has been the Chief Executive Officer of BioClinica, Inc. since January 05, 2015 and serves as its President. Dr. Hubbard is a leader in the Clinical Services and Biopharmaceutical R&D industries, with over three decades of experience including executive level positions at Pfizer, ICON, Parexel and Hoechst Marion Roussel Pharmaceuticals. Prior to joining BioClinica, Dr. Hubbard served as Senior Vice President and Worldwide Head of Development Operations for Pfizer Inc., where he directed and oversaw clinical trial operations and management of more than 450 clinical projects. He was responsible for the global clinical trial operations and management of more than 450 clinical projects from Phase 1 to 4. He has been leading pharmaceutical research and development activity for nearly thirty years and held positions of increasing responsibility in the biopharmaceutical and clinical research & development services industries. Dr. Hubbard has more than 30 years of experience in clinical research and drug development. Prior to joining Pfizer in 2010, he served as a Group President of Clinical Research Services at ICON Public Limited Company (alternate name, ICON plc) since January 2010. Dr. Hubbard served as Global President of ICON Clinical Research, Inc. (subsidiary of ICON plc) since March 2007. He served as Chief Operating Officer of ICON Clinical Research - U.S. & L.P. of ICON Plc. since October 1999 and as its President of ICON Clinical Research - U S since April 2005. He has held senior management positions at Clinical Studies, a division of Innovative Clinical Solutions, Ltd., Revlon Health Care Group, PAREXEL International Corporation and Hoechst Marion Roussel Pharmaceuticals. During his career, Dr. Hubbard is directly responsible for drug discovery and non-clinical pharmacology, clinical pharmacology, project management, product development optimization, commercial assessment of new chemical entities and clinical development operations. He has led several drug development teams to successful commercialization of new chemical entities and has participated at FDA meetings to support end of Phase 2 and end of Phase 3 data presentations for psychiatric, neurological, cardiovascular and anti-infective drugs. He has been Chairman of Association of Clinical Research Organizations since January 30, 2017. He has been a Director of Agile Therapeutics, Inc. since November 18, 2014. He has been a Director of Pennsylvania Bio since October 05, 2015. He has been a Director of BioClinica, Inc. since January 5, 2015. Dr. Hubbard was also a Founding Member of the Board of Directors of TransCelerate Biopharma, Inc. , a Business Advisory Board Member of SAFE Biopharma and an Advisory Board Member and Fundraising Vice-chair for the Children's Brain Tumor Foundation. He has been a Director of Association of Clinical Research Organizations since January 2015. He served as Director of ICON Clinical Research, L.P. He is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and served on the Special Interest Advisory Committee on Project Management. He also served as Chairman of the Fellow of the American College of Clinical Pharmacology (ACCP) Public Policy Committee from 1999 to 2007. Dr. Hubbard is a Board Certified Diplomat in Applied Pharmacology and elected to Fellow of the ACCP in 1994. Dr. Hubbard has authored and co-authored several book chapters and published numerous articles and abstracts in the areas of biopsychology, cardiovascular and autonomic pharmacology, clinical pharmacology and global drug development. He was a National Institute of Health Postdoctoral Fellow in cardiovascular and Cardiovascular Pharmacology at the University of Texas Health Sciences Center. Dr. Hubbard received a B.S. in Psychology and Biology from the University of Santa Clara and PhD in Cardiovascular Physiology from the University of Tennessee. Coll

Research Interest

 Clinical Research